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Colorectal cancer (CRC) is the third most common cancer and
cause of cancer mortality among men and women in the
United States with an incidence of 50/100,000 and mortality
rate of 16.3/100,000.1 This translates to a 5% lifetime risk of
CRC in the United States.1,2 Both the incidence and mortality
of CRC in the United States have been gradually declining over
the last decade, which is attributed to improved screening.1,2
Screening is associated with a 15 to 33% decrease inmortality
following a diagnosis of CRC, and colonoscopy with polypec-
tomy is associated with CRC prevention.3–5 While the
improvements in incidence and mortality are encouraging
given the high prevalence of CRC, there are still significant
strides to be made in primary prevention.
Early epidemiologic studies that analyzed trends in CRC
across nationalities and time provided initial evidence of the
influence of environmental factors on the incidence of CRC.6–8
These early studies have driven research focusing on preven-
tion of colorectal neoplasia with lifestyle modifications (e.g.,
exercise and dietary modification) and pharmacologic or
natural agents collectively known as chemoprevention.9
CRCs are thought to arise from cumulative histologic and
molecular changes that eventually result in abnormal
regulation of cellular function, cell growth, differentiation,
adhesion, and migration.10 The eventual endpoint of these
changes is the transformation of colonic epithelial cells to
adenomatous polyps and then into invasive carcinomas.10,11
With the well-studied sequential stepwise transformation of
colorectal neoplasms as discussed in more detail earlier in
this issue of Clinics, there are multiple targets for chemo-
preventive agents to stop this progression. It may be assumed
that prevention of cancer may also be, at least in part, due to
decreasing colorectal polyp formation.
The ideal primary preventative agent must target a step in
carcinogenesis, have efficacy, be cost-effective, have easy
administration, and have a favorable side effect profile. In
this article, we will review a wide host of primary preventa-
tive strategies to prevent colorectal adenoma and carcinoma
formation.
Lifestyle Modifications
There are several lifestyle modifications with extensive epide-
miological evidence that support primary prevention of CRC. As
most of these modifiable factors are difficult to effectively
randomize, the bulk of the evidence for these factors comes
from case–control and cohort studies. In the following sections,
we review the effects of exercise, alcohol consumption, smoking
cessation, and obesity on CRC prevention.
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Abstract Colorectal cancer (CRC) is one of the leading causes of cancer-related morbidity and
mortality worldwide. There are well-established screening protocols involving fecal
testing, radiographic, and endoscopic evaluations that have led to decreased incidence
and mortality of CRC in the United States. In addition to screening for CRC, there is
interest in preventing colorectal neoplasia by targeting the signaling pathways that have
been identified in the pathway of dysplasia progressing to carcinoma. This review will
detail the efficacy of multiple potential preventative strategies including lifestyle
changes (physical activity, alcohol use, smoking cessation, and obesity); dietary factors
(dietary patterns, calcium, vitamin D, fiber, folate, and antioxidants and micronu-
trients); and chemopreventive agents (nonsteroidal anti-inflammatory drugs, statins,
metformin, bisphosphonates, and postmenopausal hormonal therapy).
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Exercise
There is a large amount of observational data that suggest that
regular physical activity is associated with protection from
CRC.12–15 Investigators have hypothesized that interactions
between insulin-like growth factor-binding proteins (IGFBP),
higher vitamin D levels, higher amounts of water intake, anti-
inflammatory action, direct immune action, and/or decreased
fecal transit time may account for the preventative effect of
exercise.14,16 There have been several systematic reviews and
meta-analyses based on observational studies that have
evaluated the effect of exercise on CRC. In one review of 21
observational studies that included 17,683 patients with
colon cancer, a 26% reduction in the rate of colon cancer
among patients who exercised was noted (relative risk [RR]
¼ 0.73, 95% confidence interval [CI]: 0.66–0.81).17 Another
meta-analysis included 52 studies with a very similar 24%
reduction in the rate of colon cancer among patients who
exercised (RR ¼ 0.76, 95% CI ¼ 0.72–0.81).16 The exact
amount of exercise required to achieve this reduction is
unclear, with some studies suggesting walking briskly for 1
to 2 hours per week is enough to result in this reductionwhile
other studies suggest that more exercise is required.16,18,19
With the well-studied benefits of exercise on the risk of
CRC, other cancers, cardiovascular disease (CVD), and overall
health, patients should be counseled to pursue an exercise
regimen, even if this simply consists of a walking
program.16,17,20
Alcohol
There is a large amount of observational data that alcohol
consumption is related to increased risks of CRC.21,22 It is
estimated that 3.6% of cancers and 3.5% of all cancer deaths
worldwide are attributable to alcohol.23 The exact mecha-
nism of alcohol consumption triggering carcinogenesis is
unclear but seems most likely mediated by carcinogenic
metabolites such as acetaldehyde, which may directly cause
cell injury or gene mutations or indirectly cause decreased
glutathione synthesis and free radical formation.24,25
Similar to physical activity, there have been several system-
atic reviews and meta-analyses based on observational trials
with a lack of prospective randomized control trials. In one
meta-analysis that included 61 studies, a progressive dose–
response relationship between alcohol and CRC was found
with any drinkers (RR ¼ 1.12, 95% CI ¼ 1.06–1.19); medium
drinkers (2–3 drinks/day) (RR ¼ 1.21, 95% CI ¼ 1.13–1.28);
and heavy drinkers (3 drinks/day) (RR ¼ 1.52, 95% CI
¼ 1.27–1.81).21 There was no relationship observed between
light drinkers (1 drink/day) and CRC risk (RR ¼ 1.00, 95%
CI ¼ 0.95–1.05).21 Another meta-analysis that included five
cohort studies in Japan with 2,231,010 person-years studied
and 2,802 CRC cases demonstrated a similar progressive dose–
response relationship of alcohol intake and CRC risk where 23
to 45.9, 46 to 68.9, 69 to 91.9, and 92 g/day were associated
with an RR ¼ 1.42 (95% CI ¼ 1.21–1.66), RR ¼ 1.95 (95% CI
¼ 1.53–2.49), RR ¼ 2.15 (95% CI ¼ 1.74–2.64), and RR ¼ 2.96
(95% CI ¼ 2.27–3.86), respectively.26 This study also noted that
the alcohol–CRC association was stronger among Japanese
than in Western populations.26
When counseling a patient on the role of alcohol on the
primary prevention of CRC, one can state that the current
literature points to a direct dose–response relationship with
long-term alcohol use and CRC that starts at two drinks per
day and increases as the number of drinks per day increases.
Smoking Cessation
Smoking is associated with a host of cancers and health risks,
and there is strong observational evidence that smoking is
associated with adenomatous polyp formation and CRC inci-
dence and mortality.27–29 Tobacco and smoking produce a
large number of carcinogens that have been shown to directly
cause irreversible DNA damage to colorectal mucosa that can
initiate the pathway to carcinoma.30
There have been several systematic reviews and meta-
analyses based on observational studies investigating the
relationship between smoking and CRC risk. One of these
studies included 42 observational trials consisting of
15,354 cases and 100,011 controls to examine the effect
of smoking on the formation of adenomatous polyps. This
study found that in comparison with nonsmokers, current
smokers (RR ¼ 2.14, 95% CI ¼ 1.86–2.46); former
smokers (RR ¼ 1.47, 95% CI ¼ 1.29–1.67); and ever-smok-
ers (RR ¼ 1.82, 95% CI ¼ 1.65–2.00), all had significantly
increased risks of adenomas. Furthermore, there was a
relationship wherein ever-smokers had a higher rate of
high-risk adenomas.28 Another meta-analysis including
106 observational studies found that ever-smokers had a
moderately increased risk of CRC compared with non-
smokers, (RR ¼ 1.18, 95% CI ¼ 1.11–1.25) with a statisti-
cally significant dose–response relationship only after
30 years of smoking.27 This same study also reported a
higher risk of CRCmortality among ever-smokers compared
with nonsmokers (RR ¼ 1.25, 95% CI ¼ 1.14–1.37).27
Thus, while the overall risk of smoking on the rate of CRC is
moderate (18% higher risk for ever-smokers), patients
should be counselled to quit smoking both for their colorectal
neoplasia risk in addition to the risks of other cancers and
overall health status.
Obesity
The relationship between obesity and CRC has also been
assessed in observational studies.31–33 The exact mechanism
of obesity resulting in CRC is not fully understood but likely
involves modulation of endogenous hormones such as insu-
lin, insulin-like growth factors, sex steroids, and adipocyte-
derived factors (e.g., leptin and adiponectin).31,33,34
There have been several systematic reviews and meta-
analyses based on observational studies to assess the interac-
tion of obesity and CRC. One of these studies evaluated 30
prospective studies and found a 5-unit increase in BMI
corresponded to a 30% increased risk of CRC in men (RR
¼ 1.30, 95% CI ¼ 1.25–1.35) and a 12% increased riskof CRC in
women (RR ¼ 1.12, 95% CI ¼ 1.07–1.18).33 Another meta-
analysis included 13 studies and found that the highest BMI
category (not explicitly defined) compared with a reference
categorywas associatedwith an increased riskof colon cancer
(hazard ratio [HR] ¼ 1.16, 95% CI ¼ 1.08–1.24).31
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Interestingly, in this analysis, there was no benefit with each
5 kg of weight loss (HR ¼ 0.96, 95% CI ¼ 0.89–1.05) but some
mild harm for each 5 kg of weight gain (HR ¼ 1.03, 95%
CI ¼ 1.02–1.05).31
The literature does point to an association of obesity and
the incidence of CRC. It remains unclear if the association of
obesity with colorectal neoplasia is an actual relationship or
is confounded by other variables that contribute to CRC risk
(e.g., diet, exercise, and alcohol consumption). The literature
at this time also suggests that weight loss does not result in
improvements in CRC risk.31 It is reasonable to recommend
weight loss for overweight and obese patients for their overall
health, but it is unclear if this modulates their risk of CRC at
this time.
Dietary Modification and Nutritional
Supplements
Epidemiological studies of various geographic dietary pat-
terns’ impact on the incidence of CRC have led to several
studies to target chemopreventive agents for CRC. Attempts
are now being made to better define individual compounds
within diets that reduce the risk for CRC to try and identify
targeted agents for further study.
Fruits and Vegetables
Increasing intake of fruit and vegetables has been studied in a
variety of case–control and cross-sectional studies with some
controversy about efficacy.35–39 The mechanism of this pre-
vention is thought to be multifactorial with effects from
micronutrients, dietary fiber, and phytochemicals all interact-
ing tomodify colonic inflammation and CRC genemutations.40
There have been a large number of case–control series and
some prospective cohort studies to evaluate the effect of fruits
and vegetables on CRC risk. In an analysis of 14 cohort studies
that included 756,217 men and women followed up for a
period of 6 to 20 years, there was no significant difference
between the pooled RRs of CRC for thehighest- versus lowest-
quintile consumption of fruits (RR ¼ 0.91, 95% CI ¼ 0.82–
1.01), vegetables (RR ¼ 0.94, 95% CI ¼ 0.86–1.02), and fruits
and vegetables combined (RR ¼ 0.90, 95% CI ¼ 0.77–1.05).35
In the Nurses’ Health Study and Health Professional Study
including 743,645 total person-years, a difference in fruit and
vegetable consumption of one additional serving per day was
associated with no change in the rate of CRC (RR ¼ 1.02, 95%
CI ¼ 0.98–1.05).37 Another study that included 19 prospec-
tive studies demonstrated an 8% risk reduction for fruit and
vegetable use comparing the highest- to the lowest-quintile
(RR ¼ 0.92, 95% CI ¼ 0.86–0.99) which was statistically sig-
nificant.41 This relationship was not statistically significant
for any of the other quintiles of fruit and vegetable intake,
which essentiallymeant that after consuming 100 g of fruit or
vegetable per day (the equivalent of a daily apple), there is no
further expected reduction in CRC risk.41,42
In contrast to simply increasing fruit and vegetable intake,
vegetarian dietary patterns and pescovegetarian patterns did
demonstrate significant reductions in CRC rates in a trial
including 96,354 men and women with a mean follow-up of
7.3 years.43 In this trial, vegetarians had a 22% lower chance of
having CRC as compared with nonvegetarians (RR ¼ 0.78,
95% CI ¼ 0.64–0.95), and pescovegetarians had a 43% lower
chance of CRC (RR ¼ 0.57, 95% CI ¼ 0.40–0.82).43
Based on these analyses, increasing fruit and vegetable
intakemay helpwith other chronic diseases but do not appear
to significantly reduce the risk of CRC. An entirely vegetarian
or pescovegetarian dietary pattern does appear to mitigate
CRC risk.
Red Meats
Diets high in redmeat are associatedwith increased rates of CRC
in several large prospective cohort analyses.44–49 The mecha-
nism felt to drive this interaction is multifactorial with compo-
nents of direct mutagenic effect of heterocyclic amines after
meat is cooked at high temperature and formation of carcino-
genic N-nitroso compounds in the gastrointestinal tract.49
In ameta-analysis of 21prospective studies, therewas a 22%
increased rate of CRC for thehighest versus lowest intake of red
and processed meats (RR ¼ 1.22, 95% CI ¼ 1.11–1.34), and a
14% increased rate of cancer for each 100 g/day increase in red
and processed meats (RR ¼ 1.14, 95% CI ¼ 1.04–1.24).49 This
study then performed a nonlinear dose–response meta-analy-
sis which demonstrated significant increases in the rate of CRC
which was first noticed in patient populations eating as low as
20 g of meat daily.49 This effect plateaued around 140 g/day.49
There is some data that this effect is modulated by genetic
characteristics of individuals.50
When reviewing the current literature, the results of these
trials point to a mildly increased risk of CRC with red meat
consumption. This also corresponds with previously de-
scribed evidence that vegetarian and pescovegetarian diets
reduce the risk of CRC. It is important to note that red meats
do have beneficial properties including repletion of vitamin
B12 and iron, so counseling patients to limit their red meat
intake needs to take this into account.
Dietary Fat
The role of dietary fat patterns and the risk of CRC were
initially investigated in epidemiologic-based studies with
promising results, but a subsequent randomized controlled
trial demonstrated no reduction in risk.48,51,52Dietary fatwas
thought to potentially increase CRC risk via changes in cell
membrane structure and subsequent changes in cell signaling
and repair mechanisms.53,54 A large randomized control trial
which included 48,835 postmenopausal women demon-
strated no benefits with lowering dietary fat consumption on
CRC rates.51 Participants in this study were assigned no
dietary modification or intensive behavioral dietary modifi-
cation counseling designed to support reductions in dietary
fat, increased consumption of vegetables and fruit, and
increased grain servings which resulted in changes in the
intervention arm’s dietary patterns.51 However, this
decreased dietary fat intake did not change the rate of CRC
(RR ¼ 1.08, 95% CI ¼ 0.90–1.29).51 Therefore, counseling
patients on a balanced diet while minimizing saturated and
trans-unsaturated fats is appropriate for their overall health,
but it does not appear to impact rates of CRC.
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Calcium
The role calcium plays in chemoprevention of CRC has been
extensively studied, including three randomized controlled
trials and several meta-analyses.55–58 The mechanism that
drives this potential interaction ismultifactorial with calcium
directly mediating decreased inflammation in response to
bacterial flora, calcium-binding secondary bile acids or
ionized fatty acids and thus diminishing these substances’
carcinogenic properties, and calcium mediating direct reduc-
tion of cell proliferation and promotion of cell differentiation
perhaps through favorable changes on gene expression in the
APC/β-catenin pathway.57
There have been discordant results based on systemic
reviews, randomized controlled trials, and prospective cohort
studies on the role of calcium in colorectal neoplasia.57 A
Cochrane review based on two randomized controlled trials
with 1,346 subjects with a recent history of colorectal ade-
noma followed up for 3 to 4 years demonstrated a 26%
decreased rate of development of recurrent adenoma among
patients who had calcium supplementation of either 1,200
mg/day for 4 years or 2,000 mg/day for 3 years (OR ¼ 0.74,
95% CI ¼ 0.58–0.95).55,58,59 Meanwhile, a prospective, ran-
domized, double-blind, placebo-controlled trial involving
36,282 postmenopausal women where women received
1,000 mg of elemental calcium daily and 400 IU of vitamin
D3 daily or placebo for 7 years found no significant difference
in the rate of CRC formation between placebo and treatment
arms (HR ¼ 1.08, 95% CI ¼ 0.86–1.34).56Amore recentmeta-
analysis based on prospective nonrandomized observational
studies demonstrated a dose–response relationship wherein
each 300 mg/day increase in calcium was associated with an
8% reduction risk of CRC (RR ¼ 0.92, 95% CI ¼ 0.89–0.95)
from 15 studies with follow-up of 3.3 to 16 years.57
With the current available evidence, calcium supplemen-
tation is associated with approximately a 26% reduction in
adenomatous polyp formation among patients who already
have polyps.60 The optimal dose is unclear, but a dose around
1,200 to 2,000 mg is reasonable for polyp prevention. It is
unclear if this will result in CRC prevention in a general
patient population.
Vitamin D
Vitamin D has also been studied as a potential chemopreventive
agent with a variety of prospective cohort studies and one well-
designed randomized controlled trial.56,61–64 Vitamin D is
thought to act via calcitriol to regulate the cell cycle and cell
division by improving differentiation while decreasing prolifer-
ation, invasiveness, angiogenesis, and metastatic potential.61,65
A systematic review and meta-analysis was performed of
nine prospective studies and compared various plasma levels of
25-hydroxyvitamin D and 1,25-dihydroxyvitamin D with the
rate of CRC.61 This study found that the highest- versus lowest-
quantile of circulating 25-(OH)D levels experienced a 34%
decrease in the rate of CRC (OR ¼ 0.66, 95% CI ¼ 0.54–0.81).61
However, this study also made note that there are seasonal
variations in the levels of vitamin D and that patients who
exercise and takemultivitamins also tended tohavehigher levels
of vitamin D potentially confounding their results.61 Another
prospective, randomized, double-blind, placebo-controlled trial
involving 36,282 postmenopausal women where women
received 1,000 mg of elemental calcium daily and 400 IU of
vitamin D3 daily or placebo for 7 years found no significant
difference in the rate of CRC development between placebo and
treatment arms (HR ¼ 1.08, 95% CI ¼ 0.86–1.34).56 Experts
who criticized this study felt that a higher level of vitamin D3
supplementation is required (1,000 IU daily felt to be needed) to
see an effect on CRC rates and that longer follow-upwas needed
to see a change.64
Currently, there is not enough evidence to recommend for
or against vitamin D supplementation to reduce the risk of
CRC. Future randomized trials should include higher levels of
vitamin D supplementation.
Fiber
Dietary fiber is another agent studied as a possible means to
decrease CRC incidence. Burkitt noted in the early 1970s that
CRC was rare in rural Africa compared with industrial coun-
tries, which he proposed was due to dietary fiber.7 Proposed
mechanisms for a protective effect include increasing stool
bulk, decreasing colonic transit time (thus decreasing contact
time with carcinogens), binding bile acids and carcinogens,
decreasing colonic pH, and increasing the production of short
chain fatty acids.66
There have been many prospective studies and even
several randomized or quasi-randomized controlled trials
to investigate the use of fiber to decrease colorectal adenomas
and carcinomas.58,67–69 A Cochrane review including five
randomized or quasi-randomized studies of patients with a
history of adenoma who were randomized to high fiber
interventions versus control found no significant differences
in the detection of at least one adenoma (RR ¼ 1.04, 95%
CI ¼ 0.95–1.13) or more than one adenoma (RR ¼ 0.94, 95%
CI ¼ 0.77–1.15) 2 to 4 years after intervention.67 Another
prospective study that utilized the Nurse’s Health Study and
the Health Professionals Follow-up Study that included 1.8
million person-years found no protective effect of fiber on
the rate of CRC when adjusting for confounding variables
(RR ¼ 0.99, 95% CI ¼ 0.95–1.04).70 Thus, based on current
prospective evidence, fiber does not appear to have an impact
on colorectal adenoma or carcinoma formation.
Folate
Folate and folic acid received a great deal of attention when
several epidemiologic studies found a relationship between
their use and decreased CRC rates.71 Themechanism of action
of folate supplementation reducing risk of CRC stems from
deficiencies in folate resulting in differences in DNA methyl-
ation and inappropriate activation of proto-oncogenes and
therefore resulting in potential malignant transformation.72
Similar to fiber, initial promising epidemiologic and retro-
spective studies of the efficacy of folate have not been
substantiated by prospective trials. In a well-performed
meta-analysis of six randomized trials comparing folic acid
versus placebo, there was no difference in the rate of colorec-
tal adenoma among patients who had a personal history of
adenoma (RR ¼ 0.93, 95% CI ¼ 0.61–1.41).73 There was also
Clinics in Colon and Rectal Surgery Vol. 29 No. 3/2016
Prevention of Colorectal Neoplasia Dolejs et al.4
no difference noted in the rate of CRC in a general population
in patients who took folic acid versus placebo (RR ¼ 1.13, 95%
CI ¼ 0.77–1.64).73 In another well-designed randomized
controlled trial, folic acid was associated with higher risks
of having three or more adenomas and of non-CRCs.74 This
study raised the possibility that folic acid supplementation
might paradoxically increase cancer occurrence in select
patients.74
In summary, there is good evidence that folic acid and/or
folate does not decrease the rate of colorectal adenoma or
carcinoma andmay paradoxically increase the risk of colorec-
tal adenomas in select patients.
Antioxidants and Micronutrients
Based on epidemiologic data on the role fruits and vegeta-
bles play in the development of CRC, there has been a large
body of research on individual components in fruits and
vegetables that might drive CRC prevention. There are a
large number of studied compounds including phytochem-
icals, various vitamins (A, B6, B12, C, D, E), flavonoids,
resveratrol, selenium, garlic, magnesium, ginger, curcumin,
and others. A complete discussion of all of these compounds
is beyond the scope of this review. In general, while case–
control and cohort series have at times been promising for
beneficial effects for the bulk of these substances, further
investigation with prospective randomized trials has dem-
onstrated a lack of evidence that they prevent colorectal
adenoma or carcinomas.42,75–77 There are ongoing inves-
tigations into many of these compounds including in vitro
and in vivo modeling that may provide more targeted
chemotherapeutics in the future.
Chemoprevention
Nonsteroidal Anti-inflammatory Drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most
studied chemopreventive agents for CRC. There are several
proposed mechanisms through which NSAIDs cause
decreased rates of CRC. Most of these mechanisms are driven
by two interactions: NSAIDs induce apoptosis, and cyclooxy-
genase and inflammation (both of which NSAIDs inhibit) are
involved in colonic tumorigenesis.78,79
Aspirin
A recently released draft from the United States Preventive
Task Force (USPTF) on aspirin gives a grade B recommenda-
tion for low-dose aspirin use in adults aged 50 to 59 years for
primary prevention of CVD and CRC who have a 10% or
greater 10-year CVD risk, are not at increased risk for bleed-
ing, have a life expectancy of at least 10 years, and are willing
to take low-dose aspirin for 10 years.80 For patients aged 60 to
69 years, there is a grade C recommendation to individualize
the decision as towhether or not to use aspirin.80 For patients
younger than 50 years and older than 70 years, the USPTF felt
there was not enough information to make a recommenda-
tion.80 Aspirin thus represents the first chemopreventive
agent for CRC that is preliminarily being recommended for
a general population.
The efficacy of aspirin in preventing colorectal adenoma
and carcinoma progression has been investigated in several
randomized controlled trials and systemic reviews andmeta-
analyses.78,81–89 A meta-analysis that included five random-
ized controlled trials showed that regular use of aspirin
reduced the incidence of colonic adenomas by 18% (RR
¼ 0.82, 95% CI ¼ 0.7–0.95).90 Another meta-analysis that
included two large randomized trials with follow-up for
more than 20 years demonstrated that the use of aspirin at
a dose over 300 mg/day was associated with a 26% reduction
in the incidence of CRC after a latency of 10 years (HR ¼ 0.74,
95% CI ¼ 0.56–0.97).84 This study also noted that the use of
less than 300 mg/day of aspirin did not cause a reduction in
the rate of CRC.84 Another meta-analysis that included four
prospective, randomized, placebo-controlled trials with
doses of aspirin that ranged from 81 to 325 mg/day noted a
17% reduced risk of adenoma (RR ¼ 0.83, 95% CI ¼ 0.72–
0.96) and a 28% reduced risk for any advanced lesion (RR
¼ 0.72, 95% CI ¼ 0.57–0.90).86 This review did not find a
difference between higher (>160 mg/day) and lower
(<160 mg/day) dose aspirin regimens and the rate of CRC.86
Thus, based on high-quality evidence, aspirin does reduce
the risk of colorectal adenoma and carcinoma. However, the
lowest possible aspirin dose to result in reduced colorectal
neoplasia risk is unclear.
The benefit of aspirin in reducing the rate of colorectal
neoplasia has to be balanced with its risks (e.g., intestinal
bleeding and hemorrhagic strokes).80 In a systematic review
and meta-analysis of low-dose aspirin (50–325 mg/day), the
pooled risk of major intestinal bleeding (required transfusion
or hospitalization) increased significantly by 59% (odds ratio
[OR] ¼ 1.59, 95% CI ¼ 1.32–1.91) and hemorrhagic strokes
increased by 33% (OR ¼ 1.33 95% CI ¼ 1.03–1.71).91 Thus,
while there are clear benefits, there are also clear harms.
The association of aspirin and the human genome has also
been evaluated to see if aspirin use can be targeted to specific
populations who are likely to benefit from it the most. A large
prospective study found that NSAID use was associated with
lower risk of CRC, but this risk varied according to genetic
variation at two single nucleotide polymorphisms at chromo-
somes 12 and 15.92 With these results and ongoing research,
the future will likely be targeting aspirin use to populations
who are more likely to achieve benefit (both in terms of CVD
and CRC) and less likely to experience side effects.
For now, the USPTF draft recommendations seem reason-
able in recommending low-dose aspirin use in adults aged 50
to 59 years for primary prevention of CVD and CRCwhohave a
10% or greater 10-year CVD risk, are not at increased risk for
bleeding, have a life expectancy of at least 10 years, and are
willing to take low-dose aspirin for 10 years, and individual-
izing recommendations in other populations.80
Cyclooxygenase-2 Inhibitors
Cyclooxagenase-2 inhibitors (COX-2 inhibitors), including
rofecoxib and celecoxib, have been intensely studied for
CRC prevention given their decreased risk of intestinal bleed-
ing compared with aspirin with potential similar efficacy
in colorectal neoplasia prevention. In one randomized
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controlled trial, 1,435 patients with a history of adenoma
were assigned to placebo, 200 mg, or 400 mg of celecoxib
twice daily.93 At 3-year follow-up, there was a 33% reduction
in adenomas in the lower dose celecoxib group (RR ¼ 0.67,
95% CI ¼ 0.59–0.77) and a 45% reduction in adenomas in the
higher dose celecoxib group (RR ¼ 0.55, 95% CI ¼ 0.48–
0.64).93 Unfortunately, celecoxib at both dose ranges was
associated with a significantly higher risk of cardiovascular
events which caused the investigators to conclude that
celecoxib could not be routinely recommended for preven-
tion of colorectal adenomas.93 Similarly, a randomized con-
trolled trial with rofecoxib demonstrated decreased
colorectal adenoma rates but increased rates of cardiovascu-
lar events.94
Subsequent analyses have shown that celecoxib is likely
safe in patients with low-risk of CVD (either based on clinical
parameters or on low high-sensitivity C-reactive protein
levels).95,96 However, in light of moderate benefit in colorec-
tal adenoma prevention and serious risk of cardiovascular
morbidity, no society has endorsed COX-2 inhibitors for
prevention of colorectal neoplasia.
Sulindac
Sulindac, another NSAID, has also been studied in a controlled
trial that randomized 375 individualswith a history of adenoma
to sulindac and ornithine decarboxylase inhibitor difluorome-
thylornithine (DFMO) or placebo.97 This study demonstrated a
70% reduction in the rate of adenomas (RR ¼ 0.30, 95% CI
¼ 0.18–0.49) and a nonsignificant increase in adverse
events.97,98 However, use of this combination has not been
widely adopted due to concern of hearing loss and cardiovascu-
lar toxicity.42 Further studies on DFMO in combination with
other chemopreventive strategies are warranted.99
Statins
Several observational studies demonstrated that statins low-
ered the risk of CRC.100–102 The mechanism influencing
tumorigenesis is not well understood but is thought to result
from anti-inflammatory processes, inhibition of cholesterol
synthesis (which may help cell signaling for apoptosis), and
other possible apoptotic mechanisms.103
Several randomized controlled trials that investigate the
efficacy of statins have included the incidence of CRC as
secondary endpoints in their analysis. A recent systematic
review and meta-analysis of 40 studies including 8 random-
ized controlled trials, 13 cohort studies, and 19 case–control
studies involving more than 8 million subjects demonstrated
a nonsignificant reduction in the risk of CRC with statin use
within the randomized controlled trials (RR ¼ 0.89, 95%
CI ¼ 0.74–1.07) but a marginal, yet statistically significant,
effect in the cohort studies (RR ¼ 0.91, 95% CI ¼ 0.83–1.00)
and case–control studies (RR ¼ 0.92, 95% CI ¼ 0.87–0.98).
Statins do have a significant side-effect profile, including
myopathy, hepatotoxicity, and strokes.
With the current level of evidence, statins by themselves
may contribute a very modest risk reduction for CRC. In light
of significant side effects and cost, statins are not recom-
mended for use solely for CRC prevention.
Metformin
Similar to statins, the role of metformin in CRC has been
investigated as a secondary endpoint in several stud-
ies.104–109 The mechanisms of this action are still poorly
defined but are theorized to act via modulations in glucose,
insulin, insulin-like growth factor 1, IGFBP, and leptin even-
tually resulting in decreased cell growth and proliferation.104
There have been several systematic reviews of the role of
metformin on the risk of CRC. In one review with 12 random-
ized controlled trials and 41 observational studies,metformin
had no effect on the rate of CRC in the randomized controlled
trials (RR ¼ 1.02, 95% CI ¼ 0.41–2.5) but a slight reduction in
observational studies (RR ¼ 0.83, 95% CI ¼ 0.74–0.92).109 In
light of the lack of effect in randomized trials and potential
toxicity, metformin is not recommended solely for colorectal
neoplasia prevention.
Bisphosphonates
The efficacy of bisphosphonate use and cancers has been
investigated in several observational studies.110–112
Bisphosphonates are proposed to work through inhibition
of protein prenylation that eventually results in promotion of
apoptosis and inhibition of angiogenesis and tumor cell
adhesion.113 The impact of bisphosphonates on CRC was
evaluated in a systematic review and meta-analysis of three
case–control and one cohort study which demonstrated a
13% reduction in the rate of CRC (OR ¼ 0.87, 95% CI ¼ 0.78–
0.97).110 However, this study has been widely criticized, as it
excluded a large, prospective null study using the Nurses’
Health Study which showed that there was a nonsignificant
3% adjusted reduction in CRC after 5 years of use (RR ¼ 0.97,
95% CI ¼ 0.60–1.56).112 With a lack of prospective random-
ized data and inconclusive observational data, the role of
bisphosphonate therapy in colorectal neoplasia prevention is
unclear.
Postmenopausal Hormone Replacement Therapy
Postmenopausal hormone replacement therapy (HRT) was
found to reduce the risk of CRC in several epidemiological
studies.114–116 There are several proposed mechanisms
including a reduction in methylation of a DNA mismatch
repair gene and a potential induction of apoptosis via estro-
gen receptors.117 In a large randomized control trial with
16,608 postmenopausal women between 50 and 79 years of
age that compared estrogen plus medroxyprogesterone
versus placebo, a 44% reduction in the overall number of
CRCs was found in the treatment arm (RR ¼ 0.56, 95% CI
¼ 0.38–0.81).116 However, patients in the HRT group who
developed CRC had a higher rate of positive lymph nodes, a
higher stage, and a nonsignificant higher number of CRC
deaths.118 Thus, any potential gains with lower rates of CRC
diagnoses were mitigated by the more advanced stage at
diagnosis among patients taking HRT. The reason for this
association is not entirely clear. HRT is also associated with an
increased risk of breast cancer, venous thromboembolism,
coronary artery disease, stroke, and cholecystitis.115Owing to
these findings, postmenopausal HRT is not recommended for
the prevention of CRC.
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Conclusion
There is a large body of literature devoted to finding agents
and lifestyle changes that decrease the risk of colorectal
neoplasia. In general, a healthy lifestyle (exercising, minimal
alcohol consumption, smoking cessation, healthy diet, low
red meat intake) is associated with decreased CRC (and likely
decreased polyp formation or progression of polyps to can-
cer) along with improvements in other arenas of health.
Multiple chemopreventive agents have been studied with
variable results as detailed in ►Table 1. Based on current
evidence, it is reasonable to recommend calcium supplemen-
tation to prevent adenoma formation in patients with a
personal history of adenoma, although it is unclear if this
will decrease their riskof CRC. A recent draft by theUSPTFalso
recommends aspirin for CRC prevention in a specific patient
population. As we further our understanding of the complex
interplay between the human genome, the fecal microbiome,
Table 1 Different interventions with risk reductions for colorectal neoplasia
Intervention Risk reduction for CRC
(RR with 95% CI)
Recommendation
Exercise 0.76 (0.72–0.81)16 Perform regular physical activity for overall health and
colorectal neoplasia prevention
Alcohol use: heavy
drinking vs. none
1.52 (1.27–1.81)21 Limit regular alcohol intake to1 drink/day for overall health
and colorectal neoplasia prevention
Smoking 1.18 (1.11–1.25)27 Council on smoking cessation for overall health and
colorectal neoplasia prevention
Weight loss (per 5 kg lost) 0.96 (0.89–1.05)31 Weight loss likely does not change CRC risk. Reasonable to
council on weight loss for overall health
Fruit and vegetable intake
(one additional serving a day)
1.02 (0.98–1.05)37 Increasing fruit and vegetable intake likely does not change
CRC risk. Reasonable to council on weight loss for overall
health
Vegetarian diet 0.78 (0.64–0.95)43 Vegetarian diet and pescovegetarian diet appear to decrease
CRC risk
Red meats 1.22 (1.11–1.34)49 Reduction of red meats is associated with moderate reduc-
tion in colorectal neoplasia. Need supplementation of iron
and vitamin B12
Dietary fats 1.08 (0.90–1.29)51 Reduction in dietary fats does not change CRC risk.
Reasonable to council for overall health
Calcium Adenoma: 0.74 (0.58–0.95)55
Carcinoma: 1.08 (0.86–1.34)56
Recommend in patients with personal history of polyps
(1,200–2,000 mg/day). Unclear if prevents carcinoma
Vitamin D 1.08 (0.86–1.34)56 Vitamin D supplementation does not modulate risks of CRC
Fiber 0.99 (0.95–1.04)70 Fiber supplementation does not modulate risks of CRC
Folic acid 1.13 (0.77–1.64)73 Folic acid supplementation does not modulate risks of CRC
Aspirin Adenoma: 0.83 (0.72–0.96)86
Carcinoma: 0.74 (0.56–0.97)84
Recommend low-dose aspirin use in adults aged 50–59 years
for primary prevention of CVD and CRC who have a 10% or
greater 10-year CVD risk, are not at increased risk for
bleeding, have a life expectancy of at least 10 years, and are
willing to take low-dose aspirin for 10 years. Otherwise
individualize recommendations80
COX-2 inhibitor Adenoma: 0.67 (0.59–0.77)93 Good data on efficacy for colorectal adenoma prevention,
but carries increased risks of cardiovascular morbidity. Not
recommended at this time for routine use
Statins 0.89 (0.74–1.07)100 Marginal if any efficacy with considerable side effects. Not
recommended solely for CRC prevention
Metformin 1.02 (0.41–2.5)109 Likely not efficacious for CRC prevention. Not recommended
solely for CRC prevention
Bisphosphonates 0.97 (0.60–1.56)112 Conflicting studies on efficacy for colorectal neoplasia
prevention. No prospective randomized data. Not
recommended solely for CRC prevention
Postmenopausal
hormone therapy
0.56 (0.38–0.81)116 Reduction in overall incidence of CRC but no difference in
CRC mortality. Also associated with significant adverse
events. Not recommended for CRC prevention
Abbreviations: CRC, colorectal cancer; CVD, cardiovascular disease.
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and additional therapeutics, more individualized recommen-
dations about specific agents and combinations of agents to
prevent colorectal neoplasia will be made to maximize
benefit while minimizing side effects. All patients should
be encouraged to continue appropriate screening in addition
to any chosen lifestyle, dietary, and/or chemopreventive
agent(s).
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